Publications

BibTex format

@article{Vithayathil:2022:10.1111/liv.15405,
author = {Vithayathil, M and D'Alessio, A and Fulgenzi, CAM and Nishida, N and Schoenlein, M and von, Felden J and Schulze, K and Wege, H and Saeed, A and Wietharn, B and Hildebrand, H and Wu, L and Ang, C and Marron, TU and Weinmann, A and Galle, PR and Bettinger, D and Bengsch, B and Vogel, A and Balcar, L and Scheiner, B and Lee, P-C and Huang, Y-H and Amara, S and Muzaffar, M and Naqash, AR and Cammarota, A and Personeni, N and Pressiani, T and Pinter, M and Cortellini, A and Kudo, M and Rimassa, L and Pinato, DJ and Sharma, R},
doi = {10.1111/liv.15405},
journal = {Liver International},
pages = {2538--2547},
title = {Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma},
url = {http://dx.doi.org/10.1111/liv.15405},
volume = {42},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background and AimsCombination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC.Methods191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age ≥ 65 years) and younger (age < 65 years) age patients. Treatment-related adverse events (trAEs) were evaluated.ResultsThe elderly (n = 116) had higher rates of non-alcoholic fatty liver disease (19.8% vs. 2.7%; p < .001), presenting with smaller tumours (6.2 cm vs 7.9 cm, p = .02) with less portal vein thrombosis (31.9 vs. 54.7%, p = .002), with fewer patients presenting with BCLC-C stage disease (50.9 vs. 74.3%, p = .002). There was no significant difference in OS (median 14.9 vs. 15.1 months; HR 1.15, 95% CI 0.65–2.02 p = .63) and PFS (median 7.1 vs. 5.5 months; HR 1.11, 95% CI 0.54–1.92; p = .72) between older age and younger age. Older patients had similar ORR (27.6% vs. 20.0%; p = .27) and DCR (77.5% vs. 66.1%; p = .11) compared to younger patients. Atezolizumab-related (40.5% vs. 48.0%; p = .31) and bevacizumab-related (44.8% vs. 41.3%; p = .63) trAEs were comparable between groups. Rates of grade ≥3 trAEs and toxicity-related treatment discontinuation were similar between older and younger age patients. Patients 75 years and older had similar survival and safety outcomes compared to younger patients.ConclusionsAtezolizumab and bevacizumab therapy is associated with comparable efficacy and tolerability in older age patients with unresectable HCC.
AU  - Vithayathil,M
AU  - D'Alessio,A
AU  - Fulgenzi,CAM
AU  - Nishida,N
AU  - Schoenlein,M
AU  - von,Felden J
AU  - Schulze,K
AU  - Wege,H
AU  - Saeed,A
AU  - Wietharn,B
AU  - Hildebrand,H
AU  - Wu,L
AU  - Ang,C
AU  - Marron,TU
AU  - Weinmann,A
AU  - Galle,PR
AU  - Bettinger,D
AU  - Bengsch,B
AU  - Vogel,A
AU  - Balcar,L
AU  - Scheiner,B
AU  - Lee,P-C
AU  - Huang,Y-H
AU  - Amara,S
AU  - Muzaffar,M
AU  - Naqash,AR
AU  - Cammarota,A
AU  - Personeni,N
AU  - Pressiani,T
AU  - Pinter,M
AU  - Cortellini,A
AU  - Kudo,M
AU  - Rimassa,L
AU  - Pinato,DJ
AU  - Sharma,R
DO  - 10.1111/liv.15405
EP  - 2547
PY  - 2022///
SN  - 1478-3223
SP  - 2538
TI  - Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
T2  - Liver International
UR  - http://dx.doi.org/10.1111/liv.15405
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000849509200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1111/liv.15405
UR  - http://hdl.handle.net/10044/1/99888
VL  - 42
ER  -

Download

ProfessorRohiniSharma

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)